A
Vision
Rethinking Cardiovascular Risk in Europe.... to stop heart disease from being a leading cause of death.
Amarin's Innovation in Cardiovascular Disease (CVD) Management
Working together to advance pathways in cardiovascular risk management Cardiovascular disease management requires commitment and innovation. Despite optimal management of risk factors such as low-density lipoprotein cholesterol (LDL-C), many patients remain at risk of cardiovascular events.1 To reduce the burden of CVD, emerging therapeutic modalities should be explored to address drivers of residual risk.1 To provide effective cardiovascular prevention, it is crucial to share information on the evolving CVD landscape and discuss central questions in CVD management. How can we fight cardiovascular disease today?
Facing the challenges of CVD today
Read more about the impact and burden of CVD, therapeutic options and persistent risk beyond LDL-C lowering.2
Amarin in the UK
Cardiovascular disease is a persistent and growing health burden. Our ambition in the UK is to be part of the solution in addressing this important health issue.
Diversity & Inclusion
At Amarin, we value diverse perspectives, backgrounds and experiences and believe passionately that a diverse and inclusive workplace helps us to better evolve, problem-solve, be more creative and have more engaged and happy teams.
Our Product
Careers
If you are looking for a new opportunity, why not join us at Amarin ? Together we can achieve great things and improve patient's lives.
Newsroom
We've got exciting plans. Explore our latest news and stay up to date with the innovative work we're doing.
Abbreviations
CV – Cardiovascular
CVD – Cardiovascular disease
LDL-C – Low-density lipoprotein cholesterolReferences
- Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med. 2020;7:88.
- Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999-3058.
UK-NP-00362 May 2025
© 2025 Amarin Pharmaceuticals Ireland Limited.
AMARIN is a registered trademark of Amarin Pharmaceuticals Ireland Limited in the United States, European Union, United Kingdom, and other countries and regions.
Amarin UK Limited Company No: 13014219
Get In Touch
Whether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you: